Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?

Background. Currently the choice of breast cancer therapy is based on prognostic factors. The proliferation marker Ki-67 is used increasingly to determine the method of therapy. The current study analyses the predictive value of Ki-67 in foreseeing breast cancer patients’ responses to neoadjuvant ch...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2014-01, Vol.2014 (2014), p.1-7
Main Authors: Ingolf, Juhasz-Böss, Russalina, Mavrova, Simona, Moga, Julia, Radosa, Gilda, Schmidt, Bohle, Rainer M., Andrea, Hasenfus, Erich, Solomayer, Daniel, Herr
Format: Article
Language:English
Subjects:
Adjuvant treatment
Adult
Biomedical research
Biopsy
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cancer
Cancer patients
Chemotherapy
Female
Humans
Ki-67 Antigen - metabolism
Middle Aged
Mortality
Neoadjuvant Therapy
Receptor, ErbB-2 - metabolism
Retrospective Studies
Tumors
Ultrasound imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Currently the choice of breast cancer therapy is based on prognostic factors. The proliferation marker Ki-67 is used increasingly to determine the method of therapy. The current study analyses the predictive value of Ki-67 in foreseeing breast cancer patients’ responses to neoadjuvant chemotherapy. Methods. This study includes patients with invasive breast cancer treated between 2008 and 2013. The clinical response was assessed by correlating Ki-67 to histological examination, mammography, and ultrasonography findings. Results. The average Ki-67 value in our patients collectively (n=77) is 34.9 ± 24.6%. The average Ki-67 value is the highest with 37.4 ± 24.0% in patients with a pCR. The Ki-67 values do not differ significantly among the 3 groups: pCR versus partial pathological response versus stable disease/progress (P=0.896). However, Ki-67 values of patients with luminal, Her2 enriched, and basal-like cancers differed significantly from each other. Furthermore, within the group of luminal tumors Ki-67 values of patients with versus without pCR also differed significantly. Conclusion. Our data shows that the Ki-67 value predicts the response to neoadjuvant chemotherapy as a function of the molecular subtype, reflecting the daily routine concerning Ki-67 and its impressing potential and limitation as a predictive marker for neoadjuvant chemotherapy response.
ISSN:2314-6133
2314-6141
DOI:10.1155/2014/628217